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Tetraphenylborate (TPB) anions traverse membranes but are excluded
from mitochondria by the membrane potential (Dw). TPB-conjugates
also distributed across membranes in response to Dw, but surprisingly,
they rapidly entered cells. They accumulated within lysosomes
following endocystosis. This pH-independent targeting of lysosomes
makes possible new classes of probe and bioactive molecules.
The ability to direct molecules to an appropriate location within
the cell facilitates development of bioactive and probe com-
pounds. For example, molecules are targeted to the mitochondrial
matrix by conjugation to the lipophilic triphenylphosphonium
cation.1–4 The large hydrophobic surface area of the triphenylpho-
sphonium group enables rapid crossing of biological membranes
by lowering the activation energy for movement through the
membrane core.4,5 Furthermore, the positive charge drives exten-
sive accumulation within the mitochondrial matrix due to the
large membrane potential (Dc negative inside).2,4,5
To deliver molecules to other cell compartments in a similar
way, we explored conjugation to lipophilic anions. Just as the
archetypal lipophilic cation is tetraphenylphosphonium (TPP)
the corresponding lipophilic anion is tetraphenylborate (TPB).
These molecules have identical radii (4.2 Å) and, apart from
charge, are similar.6,7 Both are water soluble, facilitating bio-
logical uses, although TPB has a more negative free energy of
hydration.8 Lipophilic ions bind to a potential energy well on
the membrane surface, before flipping, to the corresponding
potential energy well on the other side of the membrane,
traversing the activation energy barrier of the membrane core
(Fig. 1).6,7,9 Hence, TPB rapidly permeates phospholipid
bilayers6,7,10,11 and its distribution is determined by the Dc,12
resulting in exclusion from the mitochondrial matrix.
TPB anions have been widely used in analytical chemistry,15
catalysis16 and solid electrolytes,17 and as substrates for oxidative18,19
and Suzuki-type cross-coupling.20,21 Despite their similar struc-
ture to TPP, and their complementary response to Dc, the use of
TPB anions to deliver compounds to different sub-cellular
compartments has not been explored. This may be because the
Dc across the plasma membrane, which is negative inside,
would be expected to disfavour intracellular delivery. There has
been only one exploration of lipophilic anion distribution
within cells, by conjugation of the monocarborane (1-carba-
closo-dodecaborate) lipophilic anion to a porphyrin.13,14 Surpri-
singly, the monocarborane conjugate was taken up by cells,14
although the mechanism was not investigated. Thus, we inves-
tigated whether TPB anions could be used to deliver com-
pounds, despite their negative charge, within the cell.
We synthesized a universal TPB-conjugate precursor 5 that
could be derivatized through amide coupling to carboxylic acids.
Fig. 1 Membrane permeation by TPB lipophilic anions (adapted from ref. 9).
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The key synthetic step was the addition of three identical phenyl
substituents to an aryltrifluoroborate (Scheme 1).22 As tetraaryl-
borates with electron-rich substituents are prone to oxidation and
protodeborylation,23 we incorporated an electron-withdrawing
sulfonamide. To assess intracellular distribution and functional
properties we made a minimal TPB derivative with the sulfona-
mide piperazine replaced with a morpholine (TPBM), to avoid
N-protonation targeting acidic compartments;24,25 a TPB conju-
gated to the chromanol group of a-tocopherol as a generic cargo
(TPBE); and two fluorescent probes, TPBCoumarin and TPBBO-
DIPY, to allow imaging.
To see if TPB-conjugates could rapidly distribute across
membranes in response to voltage we used a phospholipid
black lipid membrane (BLM) system (Fig. 2). In agreement with
previous observations,26 we detected increasing currents due to
TPB crossing a BLM as a function of voltage (Fig. 2a). In the
presence of a TPB gradient (1 mM : 10 mM) across a BLM the
reversal potential was close to the theoretical Nernst equilibrium
potential of 60 mV (Fig. 2a), demonstrating that the observed
current is caused by TPB transfer across the bilayer. At higher
TPB concentrations, but the same gradient, the current
increased and the reversal potential shifted towards 0 mV,
due to non-specific conductance caused by membrane disruption
(Fig. 2b). TPBM disrupted the BLM at lower concentrations than
TPB, leading to a larger non-specific conductance, hence the
reversal potential for TPBM was considerably lower than 60 mV
(Fig. 2c). The greater membrane disruption by TPBM compared to
TPB is caused by its enhanced lipophilicity. Therefore, only low
concentrations can be used and it was not possible to assess the
membrane permeation of TPBM and TPBE directly. Instead, to
estimate the amount of compound crossing the bilayer in
response to a voltage we measured transient ionic currents
induced by steps from 0 mV to defined voltages before/after
addition of the compounds (Fig. 2d).
In the absence of compounds the transient (capacitive) currents
are determined by the membrane’s dielectric properties. In the
presence of a TPB-conjugates the transient currents are the sum of
the capacitive current and that caused by anion redistribution.27
Charge transfer by the lipophilic anions crossing the bilayer,
derived by subtracting the current in the absence of compound,
depends on the compound concentration and the applied voltage
(Fig. 2e and f). Combined data for a +50 mV voltage jump are
shown in Fig. 2g. TPBM at 100 nM induced the largest charge flux,
while higher concentrations caused non-specific conductance. The
TPBE conductance was less (Fig. 2e and f). These results indicate
that TPB-conjugates cross a BLM in a voltage-dependent manner.
We next assessed whether TPB-conjugates crossed biological
membranes in response to a Dc using sub-mitochondrial
particles (SMPs), which are inverted mitochondrial inner
membrane vesicles (Fig. 3a). Proton pumping by the respiratory
Scheme 1 Synthesis of TPB-conjugates. Conditions: (a) (i) TFA-CH2Cl2,
0 1C – RT, 2 h (ii) ClCO2Me, 0 1C - RT, 3.5 h. (b) (i) [B(Pin)]2, Pd(dppf)Cl2,
KOAc, DMSO, 70 1C, 18 h (ii) KF, MeCN–MeOH (1 : 1), RT, 1 min (iii) L-(+)-
tartaric acid, THF, RT, 2 min (iv) MeCN 4 min (c) (i) 5 equiv. PhMgCl, THF,
0 1C, 30 min then reflux 16 h, (ii) Na2CO3(aq), RT, 1 h (iii) Bu4NBr, CH2Cl2,
RT. (d) KOH, MeOH–H2O (2 : 1) reflux, 4 h. (e) (i) RCO2H, coupling agent
(ii) ion exchange.
Fig. 2 Transport of TPB-conjugates across a Black Lipid Membrane (BLM).
Compounds were added to the both sides of a BLM to create a concen-
tration gradient. Insets show expansions of the x-axis intersection that
indicates reversal potential (Erev). (A) TPB gradient = 10 mM (cis)/1 mM (trans),
Erev B50 mV. (B) TPB gradient = 60 mM (cis)/10 mM (trans), Erev B31 mV. (C)
TPBM = 5 mM (cis)/0.5 mM (trans), Erev B32.5 mV. (D) Current recorded at 10
mV  100 nM TPBM. Inset shows magnification of the region at voltage
application. (E and F) Charge accumulated on BLM with different concen-
trations of TPBM and TPBE as a function of applied voltage. (G) Data from
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chain generates a positive-inside Dc, which should drive uptake
of lipophilic anions12 (Fig. 3a).
Using an ion-selective electrode (ISE) to measure TPB concen-
tration28 showed its rapid uptake into SMPs upon induction of a
Dc by NADH, which was reversed by dissipating the Dc with
FCCP (Fig. 3b). Similarly, TPBM (Fig. 3c) and TPBE (Fig. 3d) also
showed uptake into SMPs in response to Dc. The greater
hydrophobicity of TPBM and TPBE enhanced their membrane
adsorption compared to TPB. Therefore, TPB-conjugates rapidly
cross biological membranes in response to a Dc and adsorb
strongly to membranes.
Importantly, these attributes of TPB-conjugates are greatly
enhanced over lipophilic cations due to the different inter-
action of lipophilic anions with biological membranes. This is
primarily because of the large dipole potential from positive within
the phospholipid bilayer core to negative at the surface6,7,9,29
which lowers the activation energy barrier for lipophilic anion
transport, relative to cations, hence the membrane conductivity of
TPB is B105-fold greater than that for TPP.6,7,9–11 Similarly, the
binding constant for TPB to the potential energy well near the
membrane surface is B103–104 fold greater than for TPP.6,7,9,29
Addition of a hydrophobic linker/cargo increases this membrane
adsorption further still.
We next assessed the uptake and distribution of TPB-
conjugates using a fluorescent probe, TPBCoumarin, with C2C12
cells by confocal laser scanning microscopy (Fig. 4a and Movie 1,
ESI†). Despite its negative charge, TPBCoumarin was rapidly taken
up by cells showing punctate staining, as was TPBBODIPY (Fig. S1
and Movie 2, ESI†). Parallel staining with MitoTracker (Fig. 4b)
showed TPBCoumarin was not colocalizing with mitochondria
while LysoTracker (Fig. 4c) showed partial colocalization with
lysosomes. This suggests the punctate staining upon uptake of
TPBCoumarin is due to uptake by endocytosis with initial localiza-
tion within endosomes which then fuse with lysosomes.30 Sup-
porting this, uptake was greatly decreased by Pitstop 2 (Fig. 4d),
which inhibits clathrin-mediated endocytosis.31,32 This shows
there is rapid initial uptake by endocytosis followed by redistribu-
tion to lysosomes. Critically, there was no co-localization with
mitochondria, consistent with their exclusion from the negatively-
charged matrix. Cell toxicity of TPBE was also negligible below
10 mM (Fig. S2, ESI†).
Fig. 3 Uptake of TPB derivatives by submitochondrial particles (SMPs). (A),
Upon energization with NADH proton pumping by the respiratory chain
generates a Dc, negative inside. (B–D), An ion-selective electrode (ISE) was
calibrated (5  1 mM additions) then SMPs (0.2 mg protein per ml) were
added followed by NADH (1 mM) to generate Dc and subsequently FCCP
(1 mM) to dissipate Dc.
Fig. 4 Cell distribution of TPBCoumarin. (A), C2C12 cells were incubated
with 100 nM TPBCoumarin (green). Distribution imaged 5 min after
addition. (B) MitoTracker (red) was compared with TPBCoumarin (green).
(C) LysoTracker (magenta) compared with TPBCoumarin (green). Colocali-
zation is shown in white. (D) Cells were incubated with 20 mM Pitstop2 for
30 min before addition of TPBCoumarin and compared with control. The
bar chart shows mean  SEM of 3 independent experiments. ** p o0.01,
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Despite their negative charge, and the negative-inside Dc
across the plasma membrane, TPB display a novel intracellular
distribution. Most lysosome targeting is achieved through ion-
trapping by protonation of weak base in the acidic lysosomes.24,25
The TPBBODIPY conjugates accumulate in the same way as
TPBCoumarin (Fig. 4 and Fig. S1, Movies 1, 2, ESI†), showing
that TPB-conjugates do not require such as site. Both TPBCou-
marin and TPBBODIPY showed similar distribution in both
HeLa and Cos7 cells showing the unique distribution was not
dependent on the cell type (Fig. S3, ESI†). Their rapid endocytic
uptake is likely due to the strong binding of the TPB moiety to
the potential energy well on the membrane surface. Since TPB-
conjugates could rapidly permeate the phospholipid bilayers of
SMPs, there is also likely to be some uptake into cells directly
through the plasma membrane. However, this is disfavoured by
the plasma membrane potential (30–60 mV, negative inside).
Any TPB-conjugates that do enter may be directed to the
lysosomes in response to the negative-inside potential across
the lysosomal membrane.33 The lack of co-localization with
mitochondria is consistent with the expected thousand-fold
exclusion due to the large Dc (150–180 mV, negative inside)
across the mitochondrial inner membrane.
In summary, we have generated a new targeting group that
directs small molecules to the endosomal and lysosomal compart-
ments within the cell in a way that complements current targeting
methods that employ ion-trapping of weak bases. By manipulat-
ing hydrophobicity and incorporating cleavable linkers and
membrane impermeant moieties it will be possible to fine tune
the location and kinetics of cell distribution of bioactive mole-
cules. This approach provides new opportunities to selectively
manipulate and report on cell processes and to give a better
understanding of the role of the lysosome in autophagy34,35 and in
diseases such as cancer.36,37
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